抗α_5β_1整合素单克隆抗体类抗癌药Volociximab
被引量：1
摘要
血管生成依赖于血管细胞与成纤维细胞、血液和组织中免疫细胞以及循环系统血液成分的相互协调，而大量的研究表明，整合素在血管生成中发挥重要作用，并参与各种血管生物学过程。整合素是体内细胞广泛表达的跨膜二聚体蛋白受体，
出处
《药学进展》
CAS
2011年第4期186-187,共2页
Progress in Pharmaceutical Sciences
同被引文献21
-
1Barczyk M,Carracedo S,Gullberg D. Integrins[J]. Cell Tissue Res, 2010,339(1 ) :269-280.
-
2Goodman SL,Picard M. Integrins as therapeutic targets[J]. Ce11,2012, 33(7) :405-412.
-
3Simoons ML. Effect of glycoprotein I1 b/m a receptor blocker abcix- imab on outcome in patients with acute coronary syndromes without early coronary revascularisation :the GUSTO IV-ACS randomised trial[J]. Lancet, 2001,357 (9272) : 1915-1924.
-
4Herrmann HC,Moliterno DJ,Ohman EM,et al. Facilitation of early pereutaneous coronary intervention after reteplase with or without ab- eiximab in acute myocardial infarction:results from the SPEED (GUSTO-4 Pilot) Trial[J]. J Am Coil Cardiol,2000,36(5) : 1489-1496.
-
5Jagroop IA,Mikhailidis DP. The effect of tirofiban on fibrinogen/ago- nist-induced platelet shape change and aggregation[J]. Clin Appl Thromb Hemost, 2008,14 (3) : 295-302.
-
6Albuquerque A. Comparison of two platelet glycoprotein IIb/IIIa in- hibitors,tirofiban and abeiximab,for the prevention of ischemic events with pereutaneous coronary revascularization[J]. Rev Port Car- dial, 2001,20 ( 9 ) : 927 -928.
-
7Robert A. Inhibition of platelet glycoprotein 11 b/llla with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial In- vestigators. Platelet Glycoprotein I] b/Ina in Unstable Angina:Recep- tor Suppression Using Integrilin Therapy[J]. N Engl J Med, 1998,339 (7) :436-443.
-
8Rudick R,Polman C,Clifford D. et al. Natalizumab:bench to bedside and beyond[J]. JAMA Neurol, 2013,70(2) : 172-182.
-
9Cox D,Brennan M,Moran N. Integrins as therapeutic targets:lessons and opportunities[J]. Nat Rev Drug Discov, 2010,9 (10) : 804-820.
-
10Moruno MC, Rechenmacher F, Kessler H. Cilengitide : the first anti- angiogenic small molecule drug candidate design,synthesis and clinical evaluation[J]. Anticancer Agents Med Chem,2010,10(10): 753-768.
-
1金雪花,姜海红,刘海彤,魏冰,袁辉.瑞格列奈联合盐酸二甲双胍治疗2型糖尿病的临床效果观察[J].中国现代药物应用,2013,7(21):165-166. 被引量：12
-
2周凌,刘必成.重组人结缔组织生长因子对肾小管上皮细胞表达α5β1整合素及纤连蛋白的影响[J].药学与临床研究,2009,17(3):220-223.
-
3徐凯,朱其明,冯建鹏.免疫抑制剂的研究进展[J].医学综述,2012,18(14):2177-2180. 被引量：13
-
4李蓉,蔡辉.吡格列酮抗动脉粥样硬化作用的研究进展[J].中国动脉硬化杂志,2011,19(9):785-790. 被引量：6
-
5任秀华,斯陆勤,曹磊,姚洁,裘军,李高.多次不同剂量PEG 400对大鼠体内细胞色素P450 3A活性的影响[J].中国医院药学杂志,2008,28(22):1912-1916. 被引量：1
-
6任秀华,斯陆勤,曹磊,姚洁,裘军,李高.单次不同剂量PEG400对大鼠体内细胞色素P450 3A活性的影响[J].中国药学杂志,2009,44(5):345-348.
-
7谷舒怡,季晖,李萍.氧化应激诱导动脉粥样硬化的机制及相关治疗药物[J].药学进展,2010,34(3):110-117. 被引量：9
-
8李娟,李延团,李晓明,曹诚.分子靶向抗肿瘤药物研究进展[J].生物技术通讯,2009,20(3):411-416. 被引量：12
-
9刘史佳,居文政,陈为烤,许黎君,熊宁宁,谈恒山.血栓通注射液对大鼠体内细胞色素P450酶活性的影响[J].中国药学杂志,2010,45(2):115-118. 被引量：21
-
10赵阳.中医药对时病的预防保健[J].上海预防医学,1995,7(12):549-550.
